New cancer clinical trial: TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

Published on: November 28, 2018 at 12:00PM
Conditions:   Advanced Malignant Solid Neoplasm;   KRAS Gene Mutation;   Ovarian Carcinoma;   Refractory Malignant Solid Neoplasm;   Refractory Ovarian Carcinoma
Interventions:   Drug: Paclitaxel;   Other: Pharmacokinetic Study;   Drug: Spleen Tyrosine Kinase Inhibitor TAK-659
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Not yet recruiting
https://ift.tt/2FO9ZGU